Dr. Reddys Laboratories has issued a clarification stating that they do not comment on market speculations and there is currently no information that requires disclosure under Regulation 30 of the SEBI Listing Regulations regarding the news item about their reported interest in acquiring Biogens biosimilar products portfolio.